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Abstract
Background: Increases in pro-inflammatory cytokines are found in the brain and blood of people with schizophrenia.
However, increased cytokines are not evident in all people with schizophrenia, but are found in a subset. The cytokine
changes that best define this subset, termed the “elevated inflammatory biotype”, are still being identified.
Methods: Using quantitative RT-PCR, we measured five cytokine mRNAs (IL-1β, IL-2 IL-6, IL-8 and IL-18) from peripheral
blood of healthy controls and of people with schizophrenia or schizoaffective disorder (n = 165). We used a cluster
analysis of the transcript levels to define those with low and those with elevated levels of cytokine expression. From
the same cohort, eight cytokine proteins (IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12, IFNγ and TNFα) were measured in serum and
plasma using a Luminex Magpix-based assay. We compared peripheral mRNA and protein levels across diagnostic
groups and between those with low and elevated levels of cytokine expression according to our transcription-based
cluster analysis.
Results: We found an overall decrease in the anti-inflammatory IL-2 mRNA (p = 0.006) and an increase in three serum
cytokines, IL-6 (p = 0.010), IL-8 (p = 0.024) and TNFα (p < 0.001) in people with schizophrenia compared to healthy
controls. A greater percentage of people with schizophrenia (48%) were categorised into the elevated inflammatory
biotype compared to healthy controls (33%). The magnitude of increase in IL-1β, IL-6, IL-8 and IL-10 mRNAs in people
in the elevated inflammation biotype ranged from 100 to 220% of those in the non-elevated inflammatory biotype
and was comparable between control and schizophrenia groups. Blood cytokine protein levels did not correlate with
cytokine mRNA levels, and plasma levels of only two cytokines distinguished the elevated and low inflammatory
biotypes, with IL-1β significantly increased in the elevated cytokine control group and IL-8 significantly increased in the
elevated cytokine schizophrenia group.
Conclusions: Our results confirm that individuals with schizophrenia are more likely to have elevated levels of
inflammation compared to controls. We suggest that efforts to define inflammatory status based on peripheral
measures need to consider both mRNA and protein measures as each have distinct advantages and disadvantages
and can yield different results.
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Background
While the ubiquity of neuroinflammation in schizophre-
nia has been challenged [1], it is clear that elevated brain
cytokine expression is found in a subset of people with
schizophrenia [2–4]. It is possible that individuals with
elevated brain cytokine expression belong to a distinct
inflammatory “biotype”, in which biotype is defined as a
subset of individuals identified as being similar based on
levels of a biological marker or a combination of
biological markers [5]. Previous work in our laboratory
has shown that this apparent inflammatory biotype of
schizophrenia based on cortical cytokine expression may
also be identified in a living clinical cohort based on per-
ipheral cytokine expression [6] with ~ 40% of people
with schizophrenia classified in the elevated inflamma-
tory biotype based on measures from the post-mortem
brain or from peripheral white blood cells. Recent studies
of major depression and bipolar affective disorder by An-
drew Miller and colleagues have demonstrated the utility
of stratifying individuals by inflammatory status; they
found that those who responded to anti-inflammatory
treatment had transcriptional changes in the innate im-
mune system [7]. In clinical trials with individuals with
major depression, they showed significant improvement in
symptoms [8] after an anti-inflammatory (infliximab)
treatment and improved quality of sleep [9], but only in
those individuals with elevated inflammation defined as el-
evated C-reactive protein (CRP) levels. Such stratification
may also be helpful in schizophrenia. For example, we
have found that the high inflammatory biotype of schizo-
phrenia is more likely to display lower levels of inhibitory
interneuron markers, greater cortical grey matter reduc-
tion and signs of astrogliosis [2, 10, 11]. Identifying this
subgroup of individuals may help to determine who could
respond best to novel anti-inflammatory treatments.
In our previous studies, we found a significantly higher
proportion of people with schizophrenia versus healthy
controls with elevated cytokines and an inflammation-
associated reduction in brain volume [6, 11]. While we
found decreased cognitive ability in people with schizo-
phrenia with elevated cytokine expression, this correl-
ation was not evident in controls with elevated cytokine
expression [6]. This suggests that the peripheral inflam-
matory process may reflect altered brain and behaviour
in people with schizophrenia, more strongly than in con-
trols. Thus, in controls the tissue targeted by inflamma-
tion relating to elevated peripheral cytokines may be
outside the brain. Indeed, some individuals will have
increased inflammation due to a variety of causes (e.g.
minor infections, allergies, asthma, arthritis and auto-
immunity). Thus, the combination of overt brain dys-
function (such as psychiatric symptoms) and peripheral
inflammation may be informative of a subtype of schizo-
phrenia, but will not likely be used as a blood screen to
simply diagnose schizophrenia in isolation of the clinical
interview or patient history. However, as there are many
thousands of inflammation-related molecules that can
be measured in the blood, some further assessment as to
which molecules are most reliable and informative of
this putative subtype, the “inflammatory biotype”, of
people with schizophrenia is needed.
There have been a number of studies identifying
changes in cytokine proteins in the peripheral blood of
prodromal, first episode, acutely ill and chronically ill
people with schizophrenia. Brian Miller and colleagues
performed a meta-analysis combining data from 40 stud-
ies which demonstrated increases in peripheral protein
levels of eight pro-inflammatory cytokines [Interleukin
(IL)-1, IL-6, IL-8, IL-12, tumour necrosis factor alpha
(TNFα), transforming growth factor beta (TGF-β), inter-
feron gamma (IFNγ), soluble IL-2 receptor (sIL2R)] and
decreases in two anti-inflammatory cytokines (IL-2 and
IL-10) as well as an increase in IL-1 receptor antagonist
(IL-1RA) in chronically ill people with schizophrenia
and in people with first episode psychosis compared to
healthy controls [12]. While they showed that the levels
of three cytokines, IL-1β, IL-6 and TGF-β, appear to de-
crease with antipsychotic treatment, it is likely that these
cytokines remain elevated compared to controls as in-
creases in cytokines are typically found in chronically
medicated patients [13] as well. A recent paper from the
North American Prodrome Longitudinal Study (NAPLS),
assessing people at high-risk for schizophrenia showed
that the combination of increases in peripheral blood
levels of several interleukins (IL-1, IL-7 and IL-8) and
molecules capable of modulating the blood-brain barrier
function can be used to predict conversion to psychotic
illness [14]. Additionally, blood levels of these molecules
correlated with the degree of positive symptoms (delu-
sional ideas), cognitive deficits in attention and an increase
in dysphoric moods [14]. While increased inflammatory
signals were also found in the context of changes in
markers of stress axis dysregulation, these results suggest
that defining individuals with elevated peripheral cyto-
kines may be useful to identify those that are at high risk
of proceeding to worsening psychopathology.
We recently reported that cytokine mRNA transcripts
derived from peripheral blood may be used to identify a
subset of people with chronic schizophrenia with ele-
vated inflammation [6]. However, how these mRNA
measures correspond to the more commonly measured
changes in peripheral cytokine proteins has not been
demonstrated in people with schizophrenia. Indeed,
some studies suggest that measuring (cytokine) mRNA
expression from white blood cells may not correlate with
changes in circulating protein measurements from
plasma and serum [15–17]. Further, since there are
distinct molecular levels at which cytokine levels can be
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measured, one at the steady-state mRNA level and one
at the steady-state protein level, each requiring different
collection and assay methods, comparative data on each
measure would help to prioritise the collection methods
of ongoing and future studies in psychiatric populations.
Cytokines selected in this study were based on published
findings showing changes in specific cytokines in schizo-
phrenia by our group and others [2, 6, 12].
In the present study, we measured inflammation-
associated peripheral cytokine mRNA levels together
with protein levels in the same cohort of people with
schizophrenia compared to healthy controls. We aimed
to (1) test for schizophrenia associated peripheral cyto-
kine changes, (2) identify a subset of people with schizo-
phrenia who display increased inflammation based on
cytokine mRNA transcripts derived from white blood
cells and (3) examine if these inflammatory subgroups
show similar patterns of change in peripheral protein
levels in both serum and plasma for a range of pro- and
anti-inflammatory cytokines. We hypothesised that pro-
inflammatory cytokines may be elevated and the anti-
inflammatory IL-2 may be reduced in schizophrenia
compared to healthy controls. We expected to identify a
subgroup of people with elevated cytokine expression by
cluster analysis, and we hypothesised that this subgroup
would have proportionally more people with schizophre-
nia than healthy controls. We hypothesised that cytokine
protein changes in serum and/or plasma may be reflect-
ive of an elevated inflammatory subset as defined by ele-
vated cytokine mRNA expression.
Methods
Participants
Ninety-seven people diagnosed with schizophrenia or
schizoaffective disorder were recruited from sites in
Sydney and Adelaide, Australia, via either clinician or
self/family referral following a nationally televised docu-
mentary. All patients were living in the community and
had been receiving antipsychotic medication for at least
1 year prior to entry in the study. Patient symptom
severity scores revealed that the patients displayed mild-
to-moderate symptom severity. While the primary
purpose of recruitment was for enrolment in a double-
blind, placebo-controlled, cross-over trial of adjunctive
raloxifene [18], measures taken at baseline prior to com-
mencement of the trial were used for analysis in the
current study. To create a control group of unaffected
individuals for our case-control study, 87 healthy con-
trols were concurrently recruited through advertise-
ments at the University of New South Wales and the
local community in Sydney and Adelaide Australia. We
obtained blood samples for RNA extraction from 90 pa-
tients and 75 controls (Table 1). Plasma and serum was
measured from a subset of participants used for the
mRNA study (n = 85 and 78 patients, respectively, and
n = 71 and 65 controls, respectively).
Antipsychotic doses were obtained from the treating
physician and converted to mean daily chlorpromazine
equivalent dose [19, 20]. For 78 patients, height and
weight was collected for body mass index (BMI) cal-
culation. Diagnostic status was determined using the
Structured Clinical Interview for DSM-IV-TR (Diagnostic
and Statistical Manual of Mental Disorders 4, text
revision) [21] administered by a trained clinician and inde-
pendently confirmed by another physician.
The Positive and Negative Syndrome Scale (PANSS)
was administered by trained psychologists or psychome-
tricians to all patients to obtain measures of positive,
negative, general psychopathology and total symptom
severity [22]. Patients with a concurrent DSM-IV Axis I
psychiatric diagnosis, a history of substance abuse or de-
pendence (within the past 5 years), head injuries with
loss of consciousness, seizures, central nervous system
infections, uncontrolled diabetes or hypertension, or
mental retardation were excluded. Women were ex-
cluded if they were currently pregnant. Exclusion criteria
for the control group included a personal history of, or a
first-degree relative with a DSM-IV Axis I psychiatric
diagnosis, history of substance abuse or dependence
(within the past 5 years), head injuries with loss of con-
sciousness, seizures, central nervous system infections,
uncontrolled diabetes or hypertension, pregnancy, or
mental retardation.
Prior to participation in the study, procedures were ex-
plained and written informed consent was obtained from all
participants. The study was approved by the South Eastern
Sydney and Illawarra Area Health Services (07-259), the
University of New South Wales Human Research Ethics
Committees (07-121 and 09-187) and the Queen Elizabeth
Hospital Ethics and Human Research Committee,
Adelaide (2010188).
Sample collection and preparation
Peripheral blood was collected from all participants, in
the morning between 9 and 11 am in 9 mL acid citrate
dextrose (ACD-B) tubes (BD Biosciences, North Ryde,
New South Wales, Australia), 8 mL serum-separating
tubes (SST) (Vacutainer, Becton Dickinson, Franklin
Lakes, NJ, USA) and 9 mL ethylenediaminetetraacetic
acid (EDTA) tubes (Vacuette Vacutainer, Greiner Bio-
One, Kremsmünster, Austria).
Total RNA was extracted from white blood cells using
the Trizol method (Invitrogen, Carlsbad, CA, USA), and
cDNA was synthesised with the Invitrogen Superscript
III kit (Invitrogen, Carlsbad, CA, USA) as previously de-
scribed [23]. Plasma was collected from EDTA tubes via
centrifugation at 4 °Celsius for 15 min at 2000 x g. SST
tubes were incubated at room temperature for 30 min to
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allow the blood to clot. Upon clotting, the serum was
then collected via centrifugation at 4 °Celsius for 5 min
at 2000 x g. Plasma and serum were aliquoted into pro-
tein low-binding tubes (Eppendorf, Hamburg, Germany)
and were stored at − 80 °C.
Quantitative real-time PCR
Transcript levels were measured by quantitative PCR
using Applied Biosystems’ 7900HT Real-time PCR
system (Foster City, CA, USA). Pre-designed Taqman
Gene Expression Assays; Interleukin-1β (Hs01555410_m1),
Interleukin-2 (Hs00174114_m1), Interleukin-6 (Hs001741
31_m1), Interleukin-8 (HS00174103_m1) and Interleukin-
18 (Hs01038788_m1) (Applied Biosystems, Foster City,
CA, USA) were used to quantify expression of the cytokine
genes. Three housekeeper genes; Peptidylprolyl isomerase
A (Hs99999904_m1), TATA box binding protein (Hs004
27620_m1), and ubiquitin C (Hs00824723_m1) and its cor-
responding geometric mean was used for normalisation of
the data.
Data analyses
All analyses were done using the Statistical Package for
Social Sciences (version 23, IBM, Armonk, NY, USA) or
GraphPad Prism (version 6.04 La Jolla, CA, USA). The
alpha was set to 0.05 for all analyses.
Protein assays
Cytokines were assayed using a Luminex Magpix-based
assay (Luminex corporation, Austin, TX, USA). Eight cy-
tokines (IFNγ, TNFα, IL-1β, IL-2, IL-6, IL-8, IL-10 and
IL-12 from the Human High Sensitivity T-Cell panel
(HST-CYTOMAG60SK, Merck Millipore, Billerica, MA,
USA) were analysed, IL-18 was not compatible with the
other cytokine assays in this panel and was not mea-
sured at the protein level. Serum and plasma samples
were thawed at 4 °C and were centrifuged at 1400g to
remove any aggregate protein that may potentially ob-
struct the measurement. The supernatant was then
transferred to a fresh tube and was diluted 1:2 in assay
buffer. A 10-point standard curve with serial dilutions of
1:4 was generated using reconstituted stock standards
supplied by the manufacturer; quality controls supplied
by the manufacturer were also used to determine assay
accuracy. The data was generated using the Millipore
Analyst Software (Merck Millipore, Billerica, MA, USA),
which calculated average values against a 5-parameter
logistic standard curve corrected by background read-
ings. Plasma samples were assayed in duplicate. The
average coefficient of variance for duplicate values across
analytes for plasma was 0.75%. In plasma, the coefficient
of variance in the internal controls across all plates was
52.55%. Having found the coefficient variance between
duplicate measures in plasma to be minimal (< 2%)
Table 1 Cohort demographics
















29 (20–50) 35 (20–51) U = 2339,
p < 0.001
28 (20–50) 31 (22–49) 35 (20–51) 35 (20–50) H(3) = 13.41,
p < 0.01
Gender 36 F:39 M 37 F:53 M χ2 = 0.787,
p = 0.375
20 F:26 M 13 F:9 M 19 F:24 M 16F:23 M χ2 = 2.059,
p = 0.560
RIN ± SD 7.89 ± 1.11 7.61 ± 1.00 U = 2666.5,
p = 0.028
8.23 ± 0.60 7.79 ± 1.26 7.81 ± 0.67 7.42 ± 1.18 H(3) = 8.55,
p = 0.036
Age of onset (in years
and range)
22.7 (12–46) 22.5 (12–46) 22.8 (16–32) U = 920,
p = 0.448
Duration of illness in years 13.0 ± 7.51 12.7 (3–29) 13.8 (2–31) U = 932.5,
p = 0.382
PANSS positive 15.2 ± 4.56 15.0 ± 4.49 15.2 ± 4.43 t(80) = −0.187,
p = 0.852
PANSS negative 14.4 ± 6.13 14.8 ± 5.70 13.7 ± 6.55 U = 714,
p = 0.247
PANSS general 30.7 ± 8.80 30.3 ± 8.1 30.7 ± 9.3 U = 829,
p = 0.930




558 ± 474 546 ± 489 569 ± 501 U = 834,
p = 0.967
Body mass index 30.9 ± 6.46 30.4 ± 6.55 30.9 ± 6.41 t(69) = −0.341,
p = 0.734
Notes: All values, except age, are mean ± SD standard deviation, PANSS Positive and Negative Symptom Scale, RIN RNA integrity number
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relative to the inter-plate variance, we decided to maxi-
mise the number of samples per plate by measuring serum
samples without duplicate values. In serum, the coefficient
of variance in the internal controls across all plates was
24.03%. The average minimum detectable value across all
plates was 0.14 pg/mL for IFNγ, 0.28 pg/mL for IL-10,
0.10 pg/mL for IL-12, 0.23 pg/mL for IL-1β, 0.10 pg/mL
for IL-2, 0.05 pg/mL for IL-6, 0.40 pg/mL for IL-8 and
0.12 pg/mL for TNFα.
mRNA measures
Separate gene expression experiments were performed
for the cohort of 43 controls and 43 patients [6] and for
the additional 32 controls and 47 patients who entered
the same study at a later time point. In order to analyse
these separately run gene expression experiments as a
combined cohort, a delta delta Ct (2−ΔΔCt) analysis was
performed on cycle threshold (Ct) values of all measured
cytokines for both experiments [24, 25]. The Ct geomet-
ric mean of the three housekeeper genes was used as the
internal reference. The average ΔCt of the controls in
the first experiment (n = 41) and the average ΔCt of the
controls in the second experiment (n = 36) were used as
the calibrators. PCR efficiency across all genes averaged
87.1% ± 6.1%.
Protein concentrations and ΔΔCt mRNA expression
values were tested for normality (Shapiro-Wilk) and
homogeneity of variances (Levene’s test), IL-6 and IL-8
protein levels in the serum were log transformed to
achieve normality. If normality could not be achieved
through (log) transformation, non-parametric test were
used for analyses. Variables that may contribute to
mRNA levels (age, sex and RIN) were included as covar-
iates to the GLM (ANCOVA), but were not found to be
significant (p > 0.05) and were removed again.
To identify inflammatory subgroups based on cytokine
mRNA expression, a recursive two-step cluster analysis
was performed on the entire cohort. Since we were in-
terested in defining subgroups with increased inflamma-
tion and IL-2 is (mainly) an anti-inflammatory cytokine,
we excluded IL-2 from the clustering analysis. Any miss-
ing values were replaced by an expectation maximisation
(EM) algorithm for the four pro-inflammatory cytokines.
Only individuals with gene expression data on at least
three out of four pro-inflammatory markers were
included in the EM algorithm, others were removed
(1 patient, 3 controls). Cytokine values > 2 standard devia-
tions from the group mean were considered outliers.
Individuals were excluded from clustering if two or more
cytokines were outliers (7 patients, 4 controls). The clus-
tering was performed with 68 controls and 82 patients
(Table 1). The resulting model of three clusters had an
overall model quality (Silhouette measure) of 0.5, all four
variables (IL-18, IL-1β, IL-6, IL-8 in order of contribution)
significantly contributed to the model (≥ 0.33 on a scale
from 0.1–1.0). To test our hypothesis that people with
schizophrenia were more likely to be in the elevated cyto-
kine group than healthy controls, a one-sided Fisher exact
test was performed between the low and elevated cytokine
groups for people with schizophrenia and healthy con-
trols. Bootstrapping of the cluster algorithm was per-
formed to test the robustness of our clusters. Clustering
was performed 10,000 times on subsamples of 135 (n -
15) subjects, randomly selected without replacement.
Protein measures
A minimum detectable value replacement was per-
formed for data points below the respective minimal de-
tectable value on all protein analytes (on average, 7 data
points per analyte), with the exclusion of plasma TNFα
and IL-1β (which had a higher degree of missing data).
TNFα performed poorly in the plasma and had to be
excluded. Only 41% (n = 64) of IL-1β samples in the
plasma could be detected, plasma IL-1β was included in
further analyses but without minimum detectable value
replacement (undetectable values were spread propor-
tionally across the different groups).
Percentage difference of all groups compared to low
cytokine controls was calculated for all cytokine-mRNA
expression levels, plasma protein concentrations and
serum protein concentrations, values > two standard de-
viations from the group ((1) low cytokine control, (2) el-
evated cytokine control, (3) low cytokine schizophrenia
and (4) elevated cytokine schizophrenia) means were ex-
cluded. As no significant covariates (age, sex) were identi-
fied, differences between groups were tested with a
Kruskal-Wallis test for non-parametric data with a correc-
tion for multiple comparisons (Bonferroni). For the
schizophrenia subgroups, we tested for differences in age
of onset, duration of illness, BMI, symptom severity
(PANSS) and antipsychotic dose (chlorpromazine equiva-
lent) between the low and elevated cytokine groups.
Results
Diagnostic differences in blood cytokine measures
We found that IL-2 mRNA (ΔΔCt) was significantly
decreased in people with schizophrenia (median = 0.64)
as compared to healthy controls (median = 1.00),
U = 1898, p = 0.006 (Fig. 1). No further significant diag-
nostic differences in cytokine mRNA levels were found
(all p > 0.05).
Overall, serum IL-6 protein levels were significantly
increased (t(110) = − 2.62, p = 0.010) in people with
schizophrenia (mean = 2.24 pg/ml, SD = 1.32) compared
to healthy controls (mean = 1.73 pg/ml, SD = 1.08)
(Fig. 1). Similar results were found for IL-8 (t(110) = −2.92,
p = 0.024) and TNFα (U = 799.5, p < 0.001) proteins in the
serum which were both significantly higher in people with
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schizophrenia (IL-8 mean = 10.29 pg/ml, SD = 4.88; TNFα
median = 10.94 pg/ml) than in healthy controls (IL-8
mean = 8.13 pg/ml, SD = 2.93; TNFα median = 8.08 pg/ml)
(Fig. 1). No further significant differences were found in
the protein levels of IFNγ, IL1β, IL-2, IL-10 or IL-12 in
either serum or plasma when comparing diagnostic
groups (all p > 0.05).
Defining the high inflammatory biotypes using mRNA
clustering
The recursive two-step cluster analysis used to define
subgroups of people based on pro-inflammatory cyto-
kine mRNA levels yielded three inflammatory sub-
groups. Cluster 1 (n = 89) had a below median
expression across all four pro-inflammatory cytokines
(IL-1β, IL-6, IL-8, IL-18) and was termed “low cytokine
expression”. Cluster two (n = 50) had above median ex-
pression for two cytokines (IL-18, IL-8) and above third
quartile expression for the other two cytokines (IL-1β,
IL-6), this cluster was termed “high cytokine expression”.
The third cluster (n = 11) had above third quartile ex-
pressions for all four pro-inflammatory cytokines, all
higher than the second cluster and this subgroup was
termed “very high cytokine expression”. For further ana-
lysis, we combined cluster two and three into one group
termed “elevated cytokine expression” and compared
this group to the low cytokine expression group. Almost
half (47.6%) of the people with schizophrenia were in
the elevated cytokine expression group compared to
nearly one third (32.4%) of healthy controls with ele-
vated cytokine expression. People with schizophrenia
were significantly more likely (p = 0.042, Fisher’s exact
test) to be in the elevated cytokine expression group
than healthy controls (Fig. 2a).
No differences between low and elevated cytokine ex-
pression subgroups were found within schizophrenia for
age of disease-onset, duration of illness, symptom sever-
ity (PANSS), antipsychotics dose (chlorpromazine
equivalent), BMI or gender (Table 1).
The elevated cytokine groups showed significant (all
p ≤ 0.001, Kruskal-Wallis test with Bonferroni correc-
tion) increases compared to the low cytokine groups for
all tested cytokine mRNAs regardless of diagnosis [IL-1β
(H(3) = 73.308, p < 0.001), IL-2 (H(3) = 47.499,
p < 0.001), IL-6 (H(3) = 51.922, p < 0.001), IL-8
(H(3) = 46.788, p < 0.001), IL-18 (H(3) = 34.758,
p < 0.001)] (Fig. 2b). When compared to the low cyto-
kine control group, cytokine expression levels were in-
creased by 154% in the elevated cytokine control group,
decreased by 13% in the low cytokine schizophrenia
group and increased by 85% in the elevated cytokine
schizophrenia group. IL-2 also showed a difference be-
tween elevated cytokine controls and elevated cytokine
schizophrenia subgroups, with schizophrenia patients
being significantly (p = 0.007) lower than controls by
49%. A trend towards a significant difference was found
between low cytokine controls and low cytokine
schizophrenia in IL-2 mRNA expression (p = 0.072)
(Fig. 2b). No further effect of inflammatory subgroup
was found for any of the other cytokines. See
Additional file 1: Table S1 for a summary of all cyto-
kine mRNA results.
Fig. 1 Diagnostic differences in peripheral cytokine expression and protein concentrations. IL-2 mRNA expression level (ΔΔCt) in leukocyte cells
is significantly decreased in schizophrenia (p = 0.006). There are significant increases in serum protein concentration for the cytokines IL-6
(p = 0.010), IL-8 (p = 0.024) and TNFα (p < 0.001) in schizophrenia. Bars represent the median with 95% confidence interval (IL-2) or the mean with
standard error of mean (IL-6, IL-8 and TNFα)
Boerrigter et al. Journal of Neuroinflammation  (2017) 14:188 Page 6 of 15
Using bootstrapping to test the robustness of our clus-
ter analysis, people with schizophrenia were more likely
than healthy controls to be in the elevated cytokine ex-
pression group (p = 0.004) (Fig. 3). However, the mean
increase in the proportion of people with schizophrenia
with elevated cytokines compared to healthy controls
seemed modest at 11.4% ± 4.6.
Cytokine protein levels in the cytokine transcript defined
inflammatory subgroups
There was an overall effect of mRNA cytokine expression
group on IL-1β protein levels in the plasma (H(3) = 16.48,
p = 0.001). We found a significant increase in IL-1β in
elevated cytokine controls compared to low cytokine con-
trols [173% (p = 0.001), pairwise comparisons with adjusted
Fig. 2 Inflammatory clustering based on peripheral cytokine expression levels. A recursive two step cluster analysis with mRNA expression levels (ΔΔCt)
of the cytokines IL-18, IL-1β, IL-6 and IL-8 (in order of contribution) yielded 3 subgroups. (a). Increased differences in levels of cytokine expression as
compared to low cytokine controls were found for the elevated cytokine group (encompassing groups with high and very high cytokine expression) for
all cytokines, regardless of diagnosis (b). Bars represent the mean ± standard error (&p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001)
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p values for multiple comparisons], no other subgroup
comparisons within the IL-1β protein analyses were signifi-
cantly different (Fig. 4a). A borderline overall effect of cyto-
kine expression group was also found for IL-8 protein. IL-8
levels in the plasma (H(3) = 7.76, p = 0.051) showed a sig-
nificant 78% increase in the elevated cytokine schizophrenia
subgroup as compared to the low cytokine schizophrenia
subgroup (p = 0.047) (Fig. 4a, pairwise comparisons with
adjusted p values).
In contrast to the plasma, no effects of elevated cyto-
kine expression subgroup on cytokine (IL-1β and IL-8)
protein levels were found in the serum (Fig. 4b). No
cytokine subgroup difference was detected for IFNγ, IL-10
and IL-12 protein levels in the plasma (Fig. 5a) or the
serum (Fig. 5b). However, there was a significant main
effect of cytokine expression subgroup on TNFα protein
levels in the serum (H(3) = 18.36, p < 0.001). Pairwise
comparisons with adjusted p values showed significant in-
creases between low cytokine controls and elevated cyto-
kine schizophrenia of 45% (p = 0.016), increases between
elevated cytokine controls and low cytokine schizophrenia
of 44% (p = 0.015) and increases between elevated cyto-
kine controls and elevated cytokine schizophrenia of 64%
(p = 0.002). This shows TNFα was increased in both the
elevated and low cytokine subgroups of people with
schizophrenia in serum (Fig. 5b). See Additional file 1:
Table S1 for a summary of all protein percentage differ-
ence results.
Across level cytokine measures
We measured four cytokines (IL-1β, IL-2, IL-6 and IL-8)
using three different methods (mRNA expression,
protein levels in serum and protein levels in plasma). All
three levels showed distinct patterns of change as visua-
lised in Figs. 2b and 4. The average cytokine expression
of the four cytokines measured across mRNA and pro-
tein in serum and plasma, relative to the levels of the
low inflammation control group, is graphed in Fig. 6. As
compared to low cytokine controls; in elevated cytokine
controls on average the mRNA expression for the four
cytokines (IL-1β, IL-2, IL-6 and IL-8) was 144% higher,
the plasma cytokine proteins were 35% higher and cyto-
kine proteins were 6% higher in the serum. In the low
cytokine schizophrenia subgroup, mRNA expression was
11% lower on average; cytokine proteins were 4% higher
in the plasma and 22% higher in the serum for the four
cytokines compared to the low control subgroup. In the
elevated cytokine schizophrenia subgroup, cytokine
mRNAs were 89% higher; cytokine proteins were 25%
higher in plasma and 25% higher in serum for the four
cytokines as compared to low cytokine controls. As may
be expected from inspection of Fig. 6, no significant cor-
relations were found between mRNA expression and
protein levels in either the serum or the plasma within
individual cytokines. However, significant Spearman’s
rho correlations (correlation coefficients = 0.217–0.644,
p = 0.018– < 0.001) were found between protein levels
in the serum and plasma for IL-1β, IL-2, IL-6 and IL-8.
Similarly, we found significant Spearman’s rho correla-
tions (correlation coefficients = 0.534–0.600, all
p < 0.001) between protein levels in the serum and
plasma for the three cytokines (IL-10, IL-12 and IFNγ)
that were not measured by mRNA (Additional file 2:
Table S2).
Discussion
In this study, we found a lower level of mRNA for the
anti-inflammatory cytokine IL-2 in the blood of people
with schizophrenia. We have also shown higher levels of
three pro-inflammatory cytokines IL-6, IL-8 and TNF-α in
the serum of people with schizophrenia, indicating a role
of moderate chronic inflammation in schizophrenia. An
increase in occurrence of the “elevated cytokine subgroup”
in schizophrenia was found by measuring transcript levels
of cytokines from white blood cells. When comparing our
clustering of individuals based on mRNA from blood to
clustering of individuals based on mRNA from brain [2, 3]
overall more people fall into the elevated cytokine biotype
based on the blood mRNA expression. We did find quite
a high proportion of controls who were also classified as
having “elevated cytokines” and consequently, the differ-
ence between the proportion of people with schizophrenia
and healthy controls that fall into the elevated cytokine
subgroup is smaller when assayed in blood than in brain.
Nonetheless, our study provides further evidence that per-
ipheral cytokine mRNA levels could be used to identify a
11.4 %









Difference between the proportion of the schizophrenia group







Fig. 3 Bootstrapping results of cytokine clustering. Bootstrapped
probability distribution of the difference between the schizophrenia
and control group with elevated cytokines (grey bars). For comparison,
a probability distribution function with equal standard deviation,
representing no difference between the groups is presented next to
the actual distribution (solid black line). The cumulative probability of
people with schizophrenia being similarly or less represented in the
elevated inflammation clusters is 0.004. The mean increase in the
proportion of the schizophrenia group with elevated cytokines
compared with the control group was 11.4% ± 4.6
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subgroup of people with schizophrenia who may be in the
elevated inflammation biotype [6, 2].
Overall, in people with schizophrenia, we found a
lower mRNA expression level of IL-2, believed to be pri-
marily an anti-inflammatory cytokine, supporting earlier
findings of decreased IL-2 protein in serum/plasma of
people with schizophrenia [11]. Thus, it may be that
people with schizophrenia have a blunted ability to
dampen or attenuate unwanted inflammation via produ-
cing less IL-2. IL-2 was once thought to activate T cells,
but has recently been identified as critical in activation-
induced cell death (AICD) of autoreactive T cells [26].
Our finding of lower levels of IL-2 mRNA expression in
people with schizophrenia may also suggest that in
schizophrenia more T cells escape this important regula-
tory step and thus, people with schizophrenia may be
expected to have more self-reactive T cells. Lower levels
or lower function of IL-2 may be at least a partial ex-
planation of why more brain autoantibodies can be
found in blood and cerebrospinal fluid of people with
schizophrenia [27].
In this study, we did not reproduce our finding of up-
regulated peripheral IL-1β mRNA expression in the
overall group of people with schizophrenia, previously
Fig. 4 Cytokine protein levels per cytokine cluster. Protein concentrations normalised to the low cytokine controls for the cytokines IL-1β, IL-6,
IL-8 and IL-2 (IL-18 was not measured in the protein), showing distinct pattern differences of protein difference levels between plasma (a) and
serum (b). Significant differences were found for plasma IL-1β, between low and elevated controls (p = 0.001) and for plasma IL-8, between low
and elevated schizophrenia patients (p = 0.047). Bars represent the mean ± standard error (&p < 0.10, *p < 0.05, ***p < 0.001)
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reported in a subset of this cohort [6]. However, in this
analysis we may have introduced some variance by assay-
ing subjects at two different time points, so failure to find
overall increases should be taken with caution. IL-1β is
considered a master regulator of neuroinflammation [28],
and in this cohort, high levels of IL-1β mRNA correlated
with increased protein levels of IL6 and TNF alpha. Add-
itionally, IL-1β expression was informative in the cluster
analysis to identify the high inflammatory biotype and
tended to correspond with high levels in other cytokine
mRNA (data not shown) as found before [6] confirming
IL-1β as a major player in inflammation.
In our analysis of protein levels of cytokines, we found
significant increases in serum protein levels for the cyto-
kines IL-6, IL-8 and TNFα in the whole group of people
with schizophrenia compared to the whole group of
healthy controls. TNFα has recently been reported to
also be upregulated in the plasma of people with schizo-
phrenia [29]. Since peripheral IL-6 and TNFα are con-
sidered to be mainly macrophage-derived cytokines [30],
this suggests an over-activity of monocytes capable of
transmigrating into tissue differentiating as macrophages
and phagocytosing cellular and subcellular substrates in
tissues, possibly the brain, in people with schizophrenia.
Fig. 5 Other cytokine protein levels per cytokine cluster. Protein concentrations normalised to the low cytokine controls for the cytokines IFNγ,
IL-10 and IL-12 showed no effect of cytokine cluster groups in the plasma (a) or the serum (b). For TNFα (serum only), significant differences were
found between low cytokine control and elevated cytokine schizophrenia groups (p = 0.016), the elevated cytokine control and low cytokine
schizophrenia groups (p = 0.015) and between the elevated cytokine control and the elevated cytokine schizophrenia group (p = 0.002) (b). Bars
represent the mean ± standard error (*p < 0.05, **p < 0.01)
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In brain, we and others find an upregulation of IL-6 and
IL-8 mRNA expression in the dorsal lateral prefrontal
cortex (DLPFC) of people with schizophrenia compared
to controls [2, 4], but no change in TNFα [3, 29]. In the
brain, the resident immune cells or microglia can also
produce these pro-inflammatory cytokines and several
recent studies have identified increased activated micro-
glial binding with the PK11195 ligand in the brains of
people with schizophrenia compared to healthy controls
[31–33] corresponding to the increase in microglia
density found by direct immunohistochemical measures
in post-mortem brains by our group [2] and others
[34, 35]. A recent study by Bloomfield et al. used the
PBR28 ligand to monitor microglia activity in individuals
in two cohorts, (1) a neuroleptic naïve group at ultra-high
risk of developing schizophrenia and (2) a group with
chronic schizophrenia [36]. Importantly, they found in-
creased binding in both cohorts suggesting that changes
in microglia may be found throughout the course of
schizophrenia. Furthermore, increases in microglial bind-
ing in those at high risk of developing psychosis were
highly correlated with positive symptoms [36] similar to
the findings reported in the NAPLS study using blood bio-
markers of inflammation [14]. These studies suggest that
increases in brain microglia are most likely not secondary
to antipsychotic medications, and this proposition is fur-
ther supported by clinical work showing that antipsy-
chotics decrease cytokine expression [37–39]. However, a
few other studies suggest that microglial activation via
positon emission tomography (PET) is not easily found at
various stages of schizophrenia [40–42].
Thus, the work to date suggests that neuroinflammation
is a part of the pathophysiology of schizophrenia, may be
directly related to the experience of psychosis and may be
able to be targeted with treatment before the first full
blown episode of psychosis emerges. However, since other
imaging studies are suggesting that there may be no
change or even a reduction in the microglia-related signal
in some people with schizophrenia [1], further studies into
microglia in the schizophrenic brain are required. Our
work suggests that increases in blood cytokines, especially
in IL-6, IL-8 and TNFα, persist beyond early psychosis
and can be found in chronic patients even when stabilised
on antipsychotic medications.
Previously, we have reported that ~ 40% of people with
schizophrenia are in the high inflammatory biotype in
the blood and brain compared to 20% of healthy con-
trols in peripheral blood [6] and 10% of healthy controls
in post-mortem prefrontal cortex tissue [2]. Here, we ob-
serve a proportion of 48% of people with schizophrenia
having elevated peripheral cytokine expression levels as
compared to 32% of healthy controls, showing slightly
higher proportions of people with the elevated cytokine
biotype in both people with schizophrenia and healthy
controls. Bootstrapping demonstrated that this differ-
ence in the proportion of people with schizophrenia with
the elevated cytokine biotype relative to healthy controls
is statistically significant, but likely smaller than the 16%
reported in our primary analysis with an estimated mean
difference of ~ 11%. This difference in this clinical co-
hort based on measurements from blood is smaller than
the percentage difference in the elevated cytokine
Fig. 6 Average cytokines in mRNA, plasma and serum per cytokine cluster. Average pro-inflammatory cytokines expression (mRNA) and concentration
(plasma, serum) levels compared to low cytokine controls for the four cytokines (IL-1β, IL-6, IL-8 and IL-2) measured by mRNA expression and protein
concentrations. In elevated cytokine controls; mRNA was 144% higher, the plasma proteins were 35% higher and proteins were 6% higher in serum.
In low cytokine schizophrenia; mRNA was 11% lower, plasma protein were 4% higher and serum proteins were 22% higher. In elevated cytokine
schizophrenia, mRNA was 89% higher, plasma proteins were 25% higher and serum proteins were 25% higher
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subgroups from the perspective of measuring cytokine
mRNA in the post-mortem brain. This smaller differ-
ence may be partly explained by the many sources for
blood cytokines related to inflammation in a range of
peripheral tissues. Our results support the general con-
cession that elevated blood cytokines are not specific to
schizophrenia. Although not significant for all cytokines
in this study, the mRNA expression seems to in fact be
higher in the elevated control group than in the elevated
schizophrenia group; this could indicate that healthy
controls are able to mount more of a cytokine response
than schizophrenia patients where there may be more of
a blunted response to inflammatory triggering events.
Within the schizophrenia group, we did not find a clin-
ical difference for any of the measurements for symptom
severity (PANSS—positive, negative, general and total)
based on cytokine expression subgroup, confirming
some other studies indicating that elevated peripheral in-
flammation does not necessarily correlate with symptom
severity in chronically ill patients receiving antipsychotic
treatment [43, 44].
While the underlying cause of the cytokine dysregula-
tion we have found here is not known, decreased IL-2
[45], increased IL-6 [46], IL-8 and TNFα [47] have all
been associated with Toxoplasma gondii infections, of
which the seroprevelance is increased in schizophrenia
[48]. However, increases in IL-6, IL-8 and TNFα are also
associated with a wide variety of immune activity like
acute-phase response [49] (e.g. sepsis and viral infec-
tions) and autoimmunity [50] which also can be related
to schizophrenia [51]. Many other cytokines are associ-
ated with the response to viral and bacterial infections
for which we did not observe significant changes or were
not assessed in this study, making causality of the cyto-
kine dysregulation observed in schizophrenia at this
stage speculative. One further possibility is that certain
genetic factors may predispose people with schizophre-
nia towards immune dysregulation as a recent genome-
wide association study in schizophrenia identified genes
on the human leukocyte antigen locus as one of the
strongest associations with schizophrenia [52].
We did not find mRNA expression to correspond with
protein levels suggesting that white blood cells may not
be the main source of peripheral cytokine proteins.
Indeed, a wide range of cells are known to secrete cyto-
kines, including fibroblasts, adipocytes, endothelial cells,
neurons [53], heart- [54] and liver [55] cells. Differences
between protein concentrations in the serum and
plasma, where we found diagnostic differences for IL-6,
IL-8 and TNFα in the serum but not the plasma, are
most likely caused by the removal of some sources of cy-
tokines in the plasma. In plasma, platelets as well as fi-
brinogens are largely removed resulting in different
protein concentrations and biocompartments as
compared to serum [56, 57]. The plasma was centrifuged
without clotting, a step that should remove 95% of all plate-
lets [58]. Platelets can produce and store cytokines and
other mediators of inflammation in α-granules [59, 60].
This suggests that people with schizophrenia in our cohort
may have increased cytokine levels within the blood plate-
lets compared to healthy controls as in this cohort platelet
counts were not increased in people with schizophrenia
(data not shown).
There are several limitations of our study. The interre-
lationships between cytokines are common and complex
and an inflammatory response triggers a cascade of mo-
lecular changes. The present study provides cytokine
levels for only one snapshot in time; longitudinal studies
are required to study cytokine dysregulations in schizo-
phrenia across the disease course. A possible confound
in our study was that all patients in our study were re-
ceiving antipsychotics which are known to affect cyto-
kine levels [12]. Further, many of our patients had high
BMIs [61] which in turn can cause elevations in blood
cytokines through release of cytokines such as IL-6 and
TNFα from fat cells [62]. However, antipsychotic doses
(chlorpromazine equivalent) and BMI did not differ be-
tween normal and elevated cytokine expression groups
for people with schizophrenia in our study. In support of
our interpretation, other studies suggest that increased
incidence of elevated cytokine expression is not just an
effect of treatment or BMI. For example, Beumer et al.
showed that increases in circulating levels of IL-1β, IL-6
and TNFα are not associated with metabolic syndrome
in schizophrenia [30], and Fernandes et al. showed by
meta-analysis that CRP is not related to antipsychotic
dose in schizophrenia [63]. However, multiple bio behav-
ioural factors are known to have an effect on circulating
inflammatory markers [64] including psychological stress
[65] and depression [66], which have not been examined
in this study. The inter-plate variance of our protein as-
says, especially in the plasma was quite high. Cytokines
are not highly abundant in the periphery of relatively
healthy people [67] and most individuals were towards the
lower end of detection for these assays, which may have
increased the variability of our data. Despite this, our cyto-
kine assays did have reasonable lower limits of detection
with relatively few missing data point for most assays.
Conclusion
We have highlighted that depending on the level of
measurement (mRNA, serum- or plasma proteins), the
magnitude and even the type of cytokines that are ele-
vated in a subgroup of people with schizophrenia are
not consistent. This raises the question whether similar
biotypes can be identified when measuring blood pro-
teins instead of mRNA expression levels. Further studies
of this and other independent cohorts are required to
Boerrigter et al. Journal of Neuroinflammation  (2017) 14:188 Page 12 of 15
identify the best panel and measurement level of inflam-
matory markers in the periphery of people with schizo-
phrenia to identify the elevated cytokine biotype. In the
meantime, we advise that it may be important to collect
mRNA, serum and plasma levels for comparisons in fu-
ture studies in schizophrenia research. We suggest that
further interrogation of transcriptional changes in white
blood cells may help to identify the reasons why periph-
eral cytokines are elevated in a subset of people with
schizophrenia.
Additional files
Additional file 1: Table S1. Percentage change results. (DOCX 20 kb)
Additional file 2: Table S2. Significant correlations between serum and
plasma cytokines. (DOCX 14 kb)
Abbreviations
ACD-B: Acid citrate dextrose solution B; BMI: Body mass index; CRP: C-reactive
protein; DSM: Diagnostic and Statistical Manual of Mental Disorders;
EDTA: Ethylenediaminetetraacetic acid; GLM: General linear model;
IFNγ: Interferon gamma; IL-(x): Interleukin; IL-1RA: Interleukin-1 receptor
antagonist; PANSS: Positive and negative symptom scale; RIN: RNA integrity
number; sIL-2R: Soluble interleukin-2 receptor; SST: Serum separating tubes;
TGF-β: Transforming growth factor beta; TNFα: Tumour necrosis factor alpha
Acknowledgements
The authors would like to thank all volunteers who participated in the study.
Funding
This work was supported by the National Health and Medical Research
Council of Australia (#568807), Schizophrenia Research Institute (utilising
infrastructure funding from the NSW Ministry of Health and the Macquarie
Group Foundation), the University of New South Wales, and Neuroscience
Research Australia. CSW is a recipient of a National Health and Medical
Research Council (Australia) Principal Research Fellowship (PRF) (#1117079).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
DB contributed to the design of the experiments, performed the gene
expression experiments, performed the statistics, contributed to the
interpretation of the results and drafted the manuscript. RC contributed to
the design of- and performed the protein expression experiments. MB
designed and performed the bootstrapping experiment. VC contributed to
the interpretation of the results and drafting of the manuscript. RD, MO, CG
and DL confirmed clinical diagnosis via SCID, performed medical exams and
checked clinical histories for participants. IJ maintained the clinical database
and performed statistics. SF contributed to the design of the experiments.
TW together with CSW were responsible for the study, contributed to the
design of study, interpretation of the results and drafting the manuscript. All
authors read, edited and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the South Eastern Sydney and Illawarra Area
Health Services (07-259), the University of New South Wales Human Research
Ethics Committees (07-121 and 09-187) and the Queen Elizabeth Hospital
Ethics and Human Research Committee, Adelaide (2010188). Written consent




CSW is on an advisory board for Lundbeck, Australia Pty Ltd. and in
collaboration with Astellas Pharma Inc., Japan.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Neuroscience Research Australia, and Schizophrenia Research Institute,
Barker Street, Randwick, New South Wales 2031, Australia. 2School of
Psychiatry, University of New South Wales, Kensington, New South Wales,
Australia. 3Discipline of Psychiatry, School of Medicine, The University of
Adelaide, Adelaide, South Australia, Australia. 4Northern Adelaide Local
Health Network, Adelaide, South Australia, Australia. 5Ramsay Health Care
(SA) Mental Health, Adelaide, South Australia, Australia.
Received: 1 May 2017 Accepted: 7 September 2017
References
1. Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP.
Postmortem evidence of cerebral inflammation in schizophrenia: a
systematic review. Mol Psychiatry. 2016;21(8):1009–26.
2. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M,
Weickert CS. Increased inflammatory markers identified in the dorsolateral
prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;
18(2):206–14.
3. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of
inflammation and stress distinguish subsets of individuals with
schizophrenia and bipolar disorder. Transl Psychiatry. 2014;4:e365.
4. Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA.
Molecular mechanisms and timing of cortical immune activation in
schizophrenia. Am J Psychiatry. 2015;172(11):1112–21.
5. Weickert CS, Weickert TW, Pillai A, Buckley PF. Biomarkers in schizophrenia: a
brief conceptual consideration. Dis Markers. 2013;35(1):7.
6. Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS,
Weickert CS. Elevated peripheral cytokines characterize a subgroup of
people with schizophrenia displaying poor verbal fluency and reduced
Broca/'s area volume. Mol Psychiatry. 2016;21(8):1090–8.
7. Mehta D, Raison CL, Woolwine BJ, Haroon E, Binder EB, Miller AH, Felger JC.
Transcriptional signatures related to glucose and lipid metabolism predict
treatment response to the tumor necrosis factor antagonist infliximab in
patients with treatment-resistant depression. Brain Behav Immun.
2013;31:205–15.
8. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial
of the tumor necrosis factor antagonist infliximab for treatment-resistant
depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry.
2013;70(1):31–41.
9. Weinberger JF, Raison CL, Rye DB, Montague AR, Woolwine BJ, Felger JC,
Haroon E, Miller AH. Inhibition of tumor necrosis factor improves sleep
continuity in patients with treatment resistant depression and high
inflammation. Brain Behav Immun. 2015;47:193–200.
10. Catts VS, Wong J, Fillman SG, Fung SJ, Shannon Weickert C. Increased
expression of astrocyte markers in schizophrenia: association with
neuroinflammation. Aust N Z J Psychiatry. 2014;48(8):722–34.
11. Zhang Y, Catts VS, Sheedy D, McCrossin T, Kril JJ, Shannon Weickert C.
Cortical grey matter volume reduction in people with schizophrenia is
associated with neuro-inflammation. Transl Psychiatry. 2016;6:e982.
12. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic
effects. Biol Psychiatry. 2011;70(7):663–71.
13. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD,
Papamichail MP, Stefanis CN. Cytokine serum levels, autologous mixed
lymphocyte reaction and surface marker analysis in never medicated
and chronically medicated schizophrenic patients. Schizophr Res.
2001;47(1):13–25.
14. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD,
Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, et al. Towards a
psychosis risk blood diagnostic for persons experiencing high-risk symptoms:
preliminary results from the NAPLS project. Schizophr Bull. 2015;41(2):419–28.
Boerrigter et al. Journal of Neuroinflammation  (2017) 14:188 Page 13 of 15
15. Lin H, Joehanes R, Pilling LC, Dupuis J, Lunetta KL, Ying S-X, Benjamin EJ,
Hernandez D, Singleton A, Melzer D, et al. Whole blood gene expression
and interleukin-6 levels. Genomics. 2014;104(6, Part B):490–5.
16. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1 beta
mRNA and protein synthesis in human peripheral blood mononuclear cells.
J Biol Chem. 1990;265(18):10232–7.
17. O'Rourke RW, Kay T, Lyle EA, Traxler SA, Deveney CW, Jobe BA, Roberts CT,
Marks D, Rosenbaum JT. Alterations in peripheral blood lymphocyte
cytokine expression in obesity. Clin Exp Immunol. 2006;146(1):39–46.
18. Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A,
O'Donnell M, Galletly C, Liu D, Balzan R, et al. Adjunctive raloxifene
treatment improves attention and memory in men and women with
schizophrenia. Mol Psychiatry. 2015;20(6):685–94.
19. Bollini P, Pampallona S, Nieddu S, Bianco M, Tibaldi G, Munizza C. Indicators
of conformance with guidelines of schizophrenia treatment in mental
health services. Psychiatr Serv. 2008;59(7):782–91.
20. Woods SW. Chlorpromazine equivalent doses for the newer atypical
antipsychotics. J Clin Psychiatry. 2003;64(6):663-7.
21. First MBS, Robert L, Gibbon M, Williams JBW. Structured clinical interview for
DSM-IV-TR Axis I disorders, research version, patient edition. (SCID-I/NP).
New York: New York State Psychiatric Institute; 2002.
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
23. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T, Wong J,
Harding AJ, Sivagnanansundaram S, Hunt C, et al. Selection of reference
gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry.
2010;44(1):59–70.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2−ΔΔCT method. Methods.
2001;25(4):402–8.
25. Pfaffl MW. A new mathematical model for relative quantification in real-time
RT–PCR. Nucleic Acids Res. 2001;29(9):e45.
26. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol.
2004;172(7):3983–8.
27. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M,
Siren AL, Pardo LA, Sperling S, Mohd Jofrry S, et al. Neuropsychiatric disease
relevance of circulating anti-NMDA receptor autoantibodies depends on
blood-brain barrier integrity. Mol Psychiatry. 2014;19(10):1143–9.
28. Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of
neuroinflammation. J Neurosci Res. 2004;78(2):151–6.
29. Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, Hyde TM,
Morch RH, Hope S, Lekva T, et al. A study of TNF pathway activation in
schizophrenia and bipolar disorder in plasma and brain tissue. Schizophr
Bull. 2017;43(4):881-90.
30. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D.
Increased level of serum cytokines, chemokines and adipokines in patients
with schizophrenia is associated with disease and metabolic syndrome.
Psychoneuroendocrinology. 2012;37(12):1901–11.
31. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E,
Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, et al. Microglia
activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195
positron emission tomography study. Biol Psychiatry. 2008;64(9):820–2.
32. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC.
Neuroinflammation in schizophrenia-related psychosis: a PET study.
J Nucl Med. 2009;50(11):1801–7.
33. Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine
receptors in postmortem brains of chronic schizophrenics. J Neural Transm.
1997;104(11–12):1361–70.
34. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in
patients with psychiatric illnesses. Neurosci Lett. 1999;271(2):126–8.
35. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR
Immunoreactive microglia in frontal and temporal cortex of chronic
schizophrenics. J Neuropathol Exp Neurol. 2000;59(2):137–50.
36. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR,
Bloomfield MAP, Bonoldi I, Kalk N, Turkheimer F, et al. Microglial activity in
people at ultra high risk of psychosis and in schizophrenia: an [11C]PBR28
PET brain imaging study. Am J Psychiatry. 2016;173(1):44–52.
37. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M,
Bosis S, Colombo F, Trabattoni D, Zagliani A, et al. Cytokine profiles in
schizophrenic patients treated with risperidone: a 3-month follow-up study.
Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26(1):33–9.
38. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK,
Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia:
comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials
of intervention effectiveness study. Biol Psychiatry. 2009;66(11):1013–22.
39. Xiang Yang Zhang DFZ, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in
serum Interleukin-2, −6, and −8 levels before and during treatment with
Risperidone and haloperidol: relationship to outcome in schizophrenia.
J Clin Psychiatry. 2004;65(7):940-7.
40. Collste K, Plaven-Sigray P, Fatouros-Bergman H, Victorsson P, Schain M,
Forsberg A, Amini N, Aeinehband S, Karolinska Schizophrenia Project c,
Erhardt S, et al. Lower levels of the glial cell marker TSPO in drug-naive first-
episode psychosis patients as measured using PET and
[lsqb]11C[rsqb]PBR28. Mol Psychiatry. 2017;22(6):850-6.
41. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, Kim PK,
Ford CN, Higgs C, Hayes LN, et al. In vivo markers of inflammatory response in
recent-onset schizophrenia: a combined study using [lsqb]11C[rsqb]DPA-713 PET
and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777.
42. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, Meyer JH,
Wilson AA, Houle S, Mizrahi R. Imaging neuroinflammation in gray and
white matter in schizophrenia: an in-vivo PET study with [ 18 F]-FEPPA.
Schizophr Bull. 2015;41(1):85–93.
43. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is
associated with the severity of cognitive impairment but not of psychiatric
symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–5.
44. Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME,
Teixeira AL. Increased serum levels of inflammatory markers in chronic
institutionalized patients with schizophrenia. Neuroimmunomodulation.
2008;15(2):140–4.
45. Hammouda NA, Hegazy IH, Rashwan IA, Ali SM. Effect of interleukin-2 on
experimental acute toxoplasmosis. J Egypt Soc Parasitol. 1998;28(2):355–64.
46. Fischer H-G, Nitzgen B, Reichmann G, Hadding U. Cytokine responses
induced by Toxoplasma gondii in astrocytes and microglial cells.
Eur J Immunol. 1997;27(6):1539–48.
47. Lahmar I, Abou-Bacar A, Abdelrahman T, Guinard M, Babba H, Ben Yahia S,
Kairallah M, Speeg-Schatz C, Bourcier T, Sauer A, et al. Cytokine profiles in
toxoplasmic and viral uveitis. J Infect Dis. 2009;199(8):1239–49.
48. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for
schizophrenia: an update. Schizophr Res. 2012;38(3):642–7.
49. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
inflammation. N Engl J Med. 1999;340(6):448–54.
50. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic
cells, protects the cells from assembly of the terminal complement
components, and sustains an Antiinflammatory innate immune response:
implications for systemic autoimmunity. J Exp Med. 2000;192(9):1353–64.
51. Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmune diseases and
severe infections as risk factors for mood disorders: a nationwide study.
JAMA Psychiatry. 2013;70(8):812–20.
52. Schizophrenia Working Group of the Psychiatric Genomics C. Biological
insights from 108 schizophrenia-associated genetic loci. Nature.
2014;511(7510):421–7.
53. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory
cytokine alterations in schizophrenia: a systematic quantitative review.
Biol Psychiatry. 2008;63(8):801–8.
54. Aoyagi T, Matsui T: The Cardiomyocyte as a source of cytokines in cardiac
injury. J Cell Sci Ther 2011, 2012(0):003.
55. Dong W, Simeonova PP, Gallucci R, Matheson J, Fannin R, Montuschi P,
Flood L, Luster MI. Cytokine expression in hepatocytes: role of oxidant
stress. J Interf Cytokine Res. 1998;18(8):629–38.
56. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. Elisa and
multiplex technologies for cytokine measurement in inflammation and
aging research. J Gerontol A Biol Sci Med Sci. 2008;63(8):879–84.
57. Lundblad R. Considerations for the use of blood plasma and serum for
proteomic analysis. Int J Genomics Proteomics. 2003;1(2).
58. Chandler WL. Microparticle counts in platelet-rich and platelet-free plasma,
effect of centrifugation and sample-processing protocols. Blood Coagul
Fibrinolysis. 2013;24(2):125–32.
59. Blair P, Flaumenhaft R. Platelet α-granules: basic biology and clinical
correlates. Blood Rev. 2009;23(4):177–89.
60. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM,
French PA, Dauerman HL, Becker RC. For the platelet colloquium P: platelet
functions beyond hemostasis. J Thromb Haemost. 2009;7(11):1759–66.
Boerrigter et al. Journal of Neuroinflammation  (2017) 14:188 Page 14 of 15
61. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J,
Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain
liabilities. J Clin Psychiatry. 1999;60(6):358–63.
62. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose
tissues of obese subjects release Interleukin-6: depot difference and
regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847–50.
63. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, Nardin P,
Goncalves CA, Berk M. C-reactive protein is increased in schizophrenia but is
not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry.
2016;21(4):554–64.
64. O’Connor M-F, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME,
Hoyt MA, Martin JL, Robles TF, Sloan EK, et al. To assess, to control, to
exclude: effects of biobehavioral factors on circulating inflammatory
markers. Brain Behav Immun. 2009;23(7):887–97.
65. Segerstrom SC, Miller GE. Psychological stress and the human immune
system: a meta-analytic study of 30 years of inquiry. Psychol Bull.
2004;130(4):601–30.
66. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R,
Seligman DA, Schmidt K. The relationship of depression and stressors to
immunological assays: a meta-analytic review. Brain Behav Immun.
2001;15(3):199–226.
67. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V.
Prerequisites for cytokine measurements in clinical trials with multiplex
immunoassays. BMC Immunol. 2009;10(1):52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Boerrigter et al. Journal of Neuroinflammation  (2017) 14:188 Page 15 of 15
